{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:06:42Z","timestamp":1793869602884,"version":"4.6.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003206"],"award-info":[{"award-number":["82003206"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82222048"],"award-info":[{"award-number":["82222048"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173338"],"award-info":[{"award-number":["82173338"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160489"],"award-info":[{"award-number":["82160489"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102747"],"award-info":[{"award-number":["82102747"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303629"],"award-info":[{"award-number":["82303629"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ebiom.2025.105607","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T16:32:13Z","timestamp":1740069133000},"page":"105607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study"],"prefix":"10.1016","volume":"113","author":[{"given":"Zhe","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoulaye","family":"Karabou\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Lecoeuvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lemeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Danino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Sara","family":"Malin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte","family":"Rigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamiae","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Collon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Duchemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-7176","authenticated-orcid":false,"given":"Yongchang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1364-7463","authenticated-orcid":false,"given":"Francis","family":"L\u00e9vi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ebiom.2025.105607_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14040896","article-title":"Time-dependent efficacy of checkpoint inhibitor nivolumab: results from a pilot study in patients with metastatic non-small-cell lung cancer","volume":"14","author":"Karabou\u00e9","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.ebiom.2025.105607_bib2","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S1470-2045(21)00546-5","article-title":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study","volume":"22","author":"Qian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105607_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102220","article-title":"Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis","volume":"9","author":"Landre","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ebiom.2025.105607_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113571","article-title":"Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: an In-depth chronotherapeutic study","volume":"199","author":"Catozzi","year":"2024","journal-title":"Eur J Cancer"},{"issue":"3_suppl","key":"10.1016\/j.ebiom.2025.105607_bib5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1200\/JCO.2024.42.3_suppl.457","article-title":"Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma","volume":"42","author":"Pascale","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"3_suppl","key":"10.1016\/j.ebiom.2025.105607_bib6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2024.42.3_suppl.268","article-title":"Impact of time-of-day on nivolumab monotherapy infusion in patients with metastatic gastric cancer","volume":"42","author":"Ishizuka","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105607_bib7","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/1541-7786.MCR-21-0786","article-title":"Diurnal expression of PD-1 on tumor-associated macrophages underlies the dosing time-dependent antitumor effects of the PD-1\/PD-L1 inhibitor BMS-1 in B16\/BL6 melanoma-bearing mice","volume":"20","author":"Tsuruta","year":"2022","journal-title":"Mol Cancer Res"},{"issue":"7946","key":"10.1016\/j.ebiom.2025.105607_bib8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-022-05605-0","article-title":"Dendritic cells direct circadian anti-tumour immune responses","volume":"614","author":"Wang","year":"2023","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105607_bib9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.alit.2022.06.006","article-title":"Chronopharmacology of immune-related diseases","volume":"71","author":"Ohdo","year":"2022","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105607_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00281-021-00903-7","article-title":"Circadian rhythms in adaptive immunity and vaccination","volume":"44","author":"Cermakian","year":"2022","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.ebiom.2025.105607_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev-pharmtox-051920-095416","article-title":"Circadian regulation of drug responses: toward sex-specific and personalized chronotherapy","volume":"64","author":"L\u00e9vi","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"72","key":"10.1016\/j.ebiom.2025.105607_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abm2465","article-title":"The circadian immune system","volume":"7","author":"Wang","year":"2022","journal-title":"Sci Immunol"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105607_bib13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2217\/imt-2022-0139","article-title":"Association of circadian timing of initial infusions of immune checkpoint inhibitors with survival in advanced melanoma","volume":"15","author":"Yeung","year":"2023","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ebiom.2025.105607_bib14","doi-asserted-by":"crossref","first-page":"S835","DOI":"10.1016\/j.annonc.2021.08.1352","article-title":"967P the time of anti-PD-1 infusion improves survival outcomes by fasting conditions simulation in non-small cell lung cancer","volume":"32","author":"Vilalta","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105607_bib15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s10388-023-01006-y","article-title":"Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy","volume":"20","author":"Nomura","year":"2023","journal-title":"Esophagus"},{"issue":"16_suppl","key":"10.1016\/j.ebiom.2025.105607_bib16","doi-asserted-by":"crossref","first-page":"e21055","DOI":"10.1200\/JCO.2023.41.16_suppl.e21055","article-title":"Improved survival on morning pembrolizumab with or without chemotherapy during initial treatment for stage IV non-small cell lung cancer","volume":"41","author":"Karabou\u00e9","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ebiom.2025.105607_bib17","series-title":"Clinical Pharmacokinetics: Concepts and Applications","author":"Rowland","year":"1995"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105607_bib18","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/cpt.3339","article-title":"Multicenter pharmacokinetic and pharmacodynamic study of pembrolizumab for non-small-cell lung cancer in patients aged 75 Years and older","volume":"116","author":"Yagishita","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ebiom.2025.105607_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2022.08.018","article-title":"Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: a population pharmacokinetic analysis in real-world non-small cell lung cancer patients","volume":"173","author":"Ohuchi","year":"2022","journal-title":"Lung cancer"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105607_bib20","article-title":"Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors","volume":"9","author":"Hurkmans","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"12","key":"10.1016\/j.ebiom.2025.105607_bib21","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s40262-023-01316-5","article-title":"Prognostic value of nivolumab clearance in non-small cell lung cancer patients for survival early in treatment","volume":"62","author":"Otten","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"22","key":"10.1016\/j.ebiom.2025.105607_bib22","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.ebiom.2025.105607_bib23","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105607_bib24","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/S1470-2045(21)00639-2","article-title":"Toxicity and efficacy of chronomodulated chemotherapy: a systematic review","volume":"23","author":"Printezi","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105607_bib25","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/EDE.0b013e3181577511","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"18","author":"Vandenbroucke","year":"2007","journal-title":"Epidemiology"},{"issue":"19","key":"10.1016\/j.ebiom.2025.105607_bib26","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105607_bib27","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score >\/= 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105607_bib28","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.ebiom.2025.105607_bib29","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis","volume":"32","author":"Uno","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105607_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241364","article-title":"Restricted cubic splines for modelling periodic data","volume":"15","author":"Lusa","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2025.105607_bib31","series-title":"Regression Modeling Strategies. R Package Version 2012: 6.2-0","author":"Harrell","year":"2012"},{"key":"10.1016\/j.ebiom.2025.105607_bib32","series-title":"R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing","year":"2021"},{"key":"10.1016\/j.ebiom.2025.105607_bib33","author":"Ahlin"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105607_bib34","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1056\/NEJMra1802337","article-title":"Circadian mechanisms in medicine","volume":"384","author":"Allada","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105607_bib35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/85507","article-title":"Changing the dosing schedule minimizes the disruptive effects of interferon on clock function","volume":"7","author":"Ohdo","year":"2001","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.ebiom.2025.105607_bib36","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/jnci\/85.23.1927","article-title":"Circadian dependence of interferon antitumor activity in mice","volume":"85","author":"Koren","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105607_bib37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00002371-199211000-00001","article-title":"Improving responses in hepatomas with circadian-patterned hepatic artery infusions of recombinant interleukin-2","volume":"12","author":"Kemeny","year":"1992","journal-title":"J\u00a0Immunother (1991)"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105607_bib38","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.cell.2024.04.015","article-title":"Circadian tumor infiltration and function of CD8(+) T cells dictate immunotherapy efficacy","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105607_bib39","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41590-024-01859-0","article-title":"Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade","volume":"25","author":"Fortin","year":"2024","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105607_bib40","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.molmed.2016.03.004","article-title":"Dosing-time makes the poison: circadian regulation and pharmacotherapy","volume":"22","author":"Dallmann","year":"2016","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ebiom.2025.105607_bib41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev.pharmtox.48.113006.094626","article-title":"Circadian timing in cancer treatments","volume":"50","author":"L\u00e9vi","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9079","key":"10.1016\/j.ebiom.2025.105607_bib42","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(97)03358-8","article-title":"Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy","volume":"350","author":"L\u00e9vi","year":"1997","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105607_bib43","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0022-3565(25)23136-6","article-title":"Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice","volume":"255","author":"Boughattas","year":"1990","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"17","key":"10.1016\/j.ebiom.2025.105607_bib44","first-page":"3896","article-title":"Docetaxel chronopharmacology in mice","volume":"58","author":"Tampellini","year":"1998","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105607_bib45","first-page":"1996","article-title":"Experimental chronotherapy of mouse mammary adenocarcinoma MA13\/C with docetaxel and doxorubicin as single agents and in combination","volume":"61","author":"Granda","year":"2001","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105607_bib46","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/0008-5472.CAN-16-1322","article-title":"Circadian clock gene Bmal1 inhibits tumorigenesis and increases paclitaxel sensitivity in tongue squamous cell carcinoma","volume":"77","author":"Tang","year":"2017","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105607_bib47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A\u00a0guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"14","key":"10.1016\/j.ebiom.2025.105607_bib48","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105607_bib49","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A\u00a0randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.ebiom.2025.105607_bib50","series-title":"Role of the Circadian Timing System in the Control of Survival of Patients Receiving Immunotherapy for Cancer. Analysis of Relevant Mechanisms","author":"Karaboue","year":"2024"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425000519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425000519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T16:16:45Z","timestamp":1762618605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425000519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":50,"alternative-id":["S2352396425000519"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105607","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105607"}}